看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。( E0 P* |$ H# W! H; K
1 c7 N/ H l" r" T7 i2 ?+ Y
" a& C& o2 V1 U' A6 ~! i7 S3 kCurrently available feasibility data for possible combination strategies. . [* H( O/ K5 M6 c
————————————————————————————————
" c; E4 @+ m1 T( N: ACombination Feasibility according to preliminary data
* e; ?) y1 b3 P8 d) N) ~% n——————————————————————————————————- W) [' [% ~. V; h1 A
Bevacizumab + sorafenib Yes, reduced dose
% K( J, t% k. j- n( W% g, oBevacizumab + sunitinib† No
+ Y+ u% {# t% v( a2 X4 tBevacizumab + temsirolimus Yes
! I/ W2 ]% d' q% O& x- V' d3 y; ?Bevacizumab + everolimus Yes * _- R A% ? F" p1 P0 m* A, ]6 Y6 T
Sorafenib + sunitinib ?
% Q$ c2 s- F( Z% U# c* y$ h4 L9 jSorafenib + temsirolimus Yes, reduced dose . Z o5 B4 q% o7 p2 l) F
Sorafenib + everolimus Yes, reduced dose - e; H1 @% T; Z: k7 j
Sunitinib + temsirolimus† No 5 O2 a' i) s' p2 o8 ?2 ]4 P( f
Sunitinib + everolimus ? ! G, O( }- q7 [
Temsirolimus + everolimus ?
; _2 R) t! _% l6 b3 X' S) Y$ a————————————————————
. J% H8 a) o/ H% @& v# `, U4 p2 X†Led to US FDA warning.0 p$ X& u$ R2 }8 ~
?: As yet unattempted combination.+ [& A- `/ u* O
|